Yes, nice, at this rate we may get safety data fro

Yes, nice, at this rate we may get safety data from those patients instead of the trial. I'm guessing they will jump straight to 700mg, where the tnbc trial could take a couple months to reach that.

I was hoping for pancreatic cancer results very soon, even worse that TNBC with 5 year survival at 7% I believe. They have a very low survival rate because it is usually found late stage and it usually goes to the brain and liver, because most are ccr5 positive, ccr5 positive cancer cells tend to gravitate towards the organs, which is why they are usually more deadly.

Anyway, I say this yesterday, and thought with leronlimab, maybe they would not need the level of chemo, which is what I am assuming is causing the pain.

BTW, with OTC stocks, it is very rarely financing that moves the share price, very rare, they are on otc because financing stinks, so financing is usually not what gets them off OTC. If it happens with cydy, it will be one of the first ones. It is these type stories, like Charlie Sheen with Pro 140, where I first found cydy, it really moved the share price back in 2016. If they had the mouse data with pancreatic cancer, I feel it would be a great benefit to Alex, which would spark the ccr5/cancer story and could save many more lives. It will happen, just it stinks nothing what we know, having to wait while they could be saving lives now.

Alex Trebek: Cancer had me 'on the floor writhing in pain' between 'Jeopardy!' tapings

https://www.usatoday.com/story/life/tv/2019/0...155575001/